This summer, the Centers for Medicare and Medicaid Services published its long-awaited final rule overhauling the clinical laboratory fee schedule (CLFS). Under the Protecting Access to Medicare Act (PAMA), CMS will create a single, national fee schedule and rebase lab fees to reflect lower private sector rates. While the start date for implementing the law has been pushed back until January 1, 2018, ‘applicable’ clinical laboratories will be required to begin reporting their financial data in 2017.
As a laboratory professional, you need to understand the impact of this payment system on your laboratory’s budget and bottom line.
After participating in this webinar, you will understand:
- Which laboratories will have to submit payment data and when
- The type of information that will need to be reported and in what format
- The impact of the new fee schedule on future payment rates
- The purpose for AMA’s new Proprietary Laboratory Analyses codes
- The 2017 CPT codes and their payment rates
In addition, you will learn strategies for your lab to succeed amidst the changes being driven by the new fee schedule.
Laboratory administrators, directors, managers, compliance officers, IVD industry professionals, and others whose work involves laboratory coding and reimbursement.
Vince Stine, PhD
Director, Government Affairs, AACC, Washington DC
Charles Root, PhD, Chief Executive Officer, CodeMap®, Schaumburg, IL
Dr. Root is a widely recognized expert in clinical laboratory coding and reimbursement. He has provided consulting services for over 20 years to healthcare providers and manufacturers regarding compliance, coding, and healthcare economic issues.
Peter Kazon, JD, Senior Counsel, Alston & Bird, LLC, Washington, DC
Mr. Kazon is a senior counsel in Alston & Bird’s Washington, D.C. office concentrating
on health care law and policy. He counsels health care providers (including clinical laboratories and diagnostic companies) on regulatory issues, including Medicare reimbursement, Stark self‐referral, fraud and abuse, food and drug law, and antitrust matters.